VOL. I · 2026 · EVIDENCE-LED SUPPLEMENT RESEARCHUSA & GLOBAL EDITION
Fitlabreviews
All Reviews
Home/Ingredients/Noopept (GVS-111)
ING-148Ingredient Research Profile

Cognitive / Nootropics

Noopept (GVS-111)

Also known as: N-Phenylacetyl-L-prolylglycine ethyl ester · Omberacetam

●○○Limited Evidence

A Russian peptide nootropic 1000× more potent than piracetam by weight. Raises BDNF and NGF acutely. Human evidence is limited but mechanistically compelling.

Effective Dose

10–30mg / day

per clinical evidence

Evidence Level

Limited

Cognitive / Nootropics

Mechanism

BDNF and NGF upregulation, AMPA receptor potentiation, acetylcholine sensitisation

primary action

Best For

Memory

Focus, Neuroplasticity

This profile is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare professional before starting any supplementation, especially if you have pre-existing conditions or take medications.

What Is Noopept (GVS-111)?

Noopept (GVS-111) is a synthetic peptide developed in Russia as a more potent piracetam analogue. It is hydrolysed in the body to cycloprolylglycine — an endogenous neuropeptide with AMPA receptor potentiating and neurotrophic-stimulating activity. Unlike racetams, it is active at much lower doses and crosses the BBB efficiently.

How It Works: The Science

Noopept potentiates AMPA receptors (increasing synaptic glutamate signalling and LTP — long-term potentiation, the cellular basis of memory). It upregulates BDNF and NGF mRNA in the hippocampus and cortex — supporting neuroplasticity. It also enhances acetylcholine sensitivity in cholinergic neurons.

Primary Mechanism

BDNF and NGF upregulation, AMPA receptor potentiation, acetylcholine sensitisation

Evidence-Based Benefits

Improves memory consolidation and neuroplasticity markers

limited

Ostrovskaya et al. (2001) — animal studies and small Russian human trials; no large Western RCT

Dosage Guide

Effective Dose

10–30mg / day

10–30mg/day, typically 10mg twice daily. Sublingually absorbed for faster onset. Cycle: 1.5–2 months on, 1 month off to prevent receptor downregulation.

Safety Profile & Side Effects

Limited long-term human safety data. Legal status varies by country. Not approved as a pharmaceutical in the West — sold as a research chemical in many jurisdictions.

Who Should (and Shouldn't) Take It

Best for
MemoryFocusNeuroplasticity
Who it's for

Experienced nootropic users who have exhausted evidence-based options (bacopa, alpha-GPC, lion's mane). Approach with appropriate caution given limited regulatory oversight.

Frequently Asked Questions

What is the recommended dose of Noopept (GVS-111)?

10–30mg/day, typically 10mg twice daily. Sublingually absorbed for faster onset. Cycle: 1.5–2 months on, 1 month off to prevent receptor downregulation.

Is Noopept (GVS-111) safe?

Limited long-term human safety data. Legal status varies by country. Not approved as a pharmaceutical in the West — sold as a research chemical in many jurisdictions.

How does Noopept (GVS-111) work?

Noopept potentiates AMPA receptors (increasing synaptic glutamate signalling and LTP — long-term potentiation, the cellular basis of memory). It upregulates BDNF and NGF mRNA in the hippocampus and cortex — supporting neuroplasticity. It also enhances acetylcholine sensitivity in cholinergic neurons.

Who should take Noopept (GVS-111)?

Experienced nootropic users who have exhausted evidence-based options (bacopa, alpha-GPC, lion's mane). Approach with appropriate caution given limited regulatory oversight.

Related Ingredients

Alpha-GPCBacopa MonnieriLion's Mane Mushroom

Medical Disclaimer

Ingredient profiles are for informational purposes only and do not constitute medical advice. Consult a qualified healthcare professional before starting any supplementation, especially if you have pre-existing conditions or take medications. Full disclaimer →